MSB Trading 2020 - a new dawn, page-8373

Appreciate you sharing with us As the usual suspects although Citigroup is a new one to me, on behalf of MnG maybe? The churn artists Credit Suisse and UBS top in volumes. Their shorts positions did well and the buybacks may be masked in the buyside volume for return. Seems like a bit of limbo at present, not sure which direction the company is headed market/trading wise. Good SP holding over Cap Raise @ 3.20....whether its support by insto's who have a chunk I can only assume.News will be in a bit of a "flash" point as next moves dictate the rest of calendar year 2020 direction. Somehow I don't think Covid results can be bundled into anything to support GVHD data, 2 completely different applications, sure its phase 3 but any result will not count against the other ones CRL in the slightest.Recent CRL against MYX saw them tank bout 17% on release.....the road seems longer for AU bio's lately.Delayed results from CHF and CLBP is a some concern still to me, back to the drawing board re:Ryoncil hangs like a cloud. All that pre-market work just fell in a heap, for now. Had to relegate to rank outsider once again.....slight reduction in exposure 5/10/20 at $3.54 but would like to see a timetable for FDA type A meeting and any way forward, feel the hurdle is firmly in place and pretty much "new" trial in Adult although past the planning stage will see a setback of at least 6 months, just my tilt.October a write-off potential wise...bring on November but no more delays to results, as the market will read only negative, another hiccup would see support stretched. Covid 45% feels unlikely to get a premature nod, although at least the trial design fits the FDA bill....apparently?Shorts as over 7.5% of issued stock on 30th Sept made some hay....churn continues with 6th Oct 4.49 million shorts traded on 17 million volume